nctId: NCT06304233 id: 606103 briefTitle: The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease overallStatus: RECRUITING date: 2023-12-13 date: 2024-12 date: 2038-06 date: 2024-03-12 date: 2024-03-12 name: Norwegian University of Science and Technology class: OTHER name: St. Olavs Hospital briefSummary: To study the association between DISC1 RNA expression levels and cardiac function in patients with schizophrenia. conditions: Heart Diseases conditions: Heart; Functional Disturbance conditions: Schizophrenia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: Echocardiography name: Cardiac Magnetic Resonance Imaging name: Electrocardiography name: Blood sampling measure: Left Ventricular Ejection Fraction (LVEF) measured by 2D Echocardiography measure: Left Ventricular Ejection Fraction (LVEF) measured by 3D Echocardiography measure: DISC1 mRNA quantification measure: Levels of high sensitive-CRP measure: Levels of CK-MB measure: Levels of Troponin T measure: Levels of Troponin I measure: Normalized Left Ventricular End-Diastolic Volume (LV EDV), echocardiographic parameter measure: Normalized Right Ventricular End-Diastolic Volume (RV EDV), echocardiographic parameter measure: Normalized left Ventricular End-Systolic Volume (LV ESV), echocardiographic parameter measure: Normalized Right Ventricular End-Systolic Volume (RV ESV), echocardiographic parameter measure: Left ventricular mass measured by echocardiography measure: Left ventricular septal thickness, left ventricular posterior wall thickness and right ventricular wall thickness measured by echocardiography measure: Fractional shortening measured by echocardiography measure: Global longitudinal strain (GLS), echocardiographic parameter measure: TAPSE echocardiographic parameter of right ventricular longitudinal systolic function measure: Echocardiographic parameter MPI, Myocardial performance index measure: Echocardiographic parameter Mitral E/A ratio measure: Echocardiography parameter of peak E velocity measure: Echocardiography parameter of E wave deceleration time measure: Echocardiography parameter of ratio of E/e' measure: Echocardiographic parameters septal e' and lateral e' velocities measure: Echocardiographic parameter LAVI, left atrial volume indexed measure: Echocardiographic parameter TRpV, Tricuspid Regurgitation peak Velocity measure: Echocardiographic parameter, S wave velocity measure: Echocardiographic parameter, Indexed LV and RV stroke volumes measure: Levels of NT-proBNP measure: Levels of IGF1 measure: Levels of ANP measure: Levels of BDNF, brain derived neurotrophic factor measure: Levels of Tumor Necrosis Factor alpha measure: Levels of Transforming Growth Factor Beta measure: Levels of cardiac Myosin-Binding Protein C measure: Interleukin levels measure: native T1 time, cardiac MRI measure: Indexed LV and RV end-diastolic, end-systolic and stroke volumes, cardiac MRI measure: Indexed LV mass, cardiac MRI measure: LV Ejection Fraction, cardiac MRI measure: ECG corrected QT interval measure: Number of participants with and abnormal ECG measure: Number of participants with abnormal liver function measure: Number of participants with abnormal kidney function measure: Number of participants with abnormal thyroid function measure: Number of participants with low Vitamin D levels measure: Incidence of cardiovascular disease or mortality as registered in a health registry on follow up measure: Triglyceride levels measure: High-density lipoprotein, HDL-cholesterol levels measure: Low-density lipoprotein, LDL-cholesterol levels measure: Fasting glucose levels measure: Glycated Hemoglobin (HbA1c) levels measure: Heart rate measured on ECG measure: Systolic Blood Pressure measure: Diastolic Blood Pressure measure: Lipoprotein a measure: Magnesium levels measure: Calcium levels measure: Sodium levels measure: Potassium levels measure: Alcohol intake at baseline using The Alcohol Use Disorders Identification Test Consumption (AUDIT-C) questionnaire measure: Average length of inpatient stay for schizophrenia related admissions measure: Need of Care based on number of total hospital admission for schizophrenia measure: Severity scoring of psychiatric symptoms using Clinical Global Impressions (CGI) Scale - Severity measure: Schizophrenia symptom severity as scored on the Positive and Negative Syndrome Scale (PANSS) measure: Duration of schizophrenia measure: Length of treatment with an antipsychotic medication measure: Antipsychotic dosage in daily equivalent dosage of chlorpromazine measure: Smoking status measure: Waist Hip Ratio measure: Body Mass Index measure: Body fat percent measure: Physical Activity measure: Body muscle composition measure: Smoking history measure: Age of participant measure: Gender of participant sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Norwegian University of Science and Technology status: RECRUITING city: Trondheim country: Norway name: Morten A Høydal, PhD role: CONTACT phone: +47 48134843 email: morten.hoydal@ntnu.no name: Rita Brekke, MD, MSc role: CONTACT phone: +47 45111574 email: rita.brekke@ntnu.no lat: 63.43049 lon: 10.39506 facility: St Olavs Hospital, Trondheim University Hospital status: RECRUITING city: Trondheim country: Norway name: Mette E Tunset, MD role: CONTACT email: mette.elise.tunset@stolav.no name: Morten B Schou, PhD role: CONTACT email: morten.brix.schou@stolav.no lat: 63.43049 lon: 10.39506 hasResults: False